type of report	**Current report**
number	87/2012
company	PHARMENA

Conclusion of the genotoxicological studies of 1-MNA

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and the Company's announcement on the realisation of the Company's Strategy in the area of dietary supplement 1-MNA (published in current report no. 61/2012 of 17th September 2012), the Management Board of PHARMENA S.A. informs of conclusion of the genotoxicological studies of 1-MNA, which are indispensable to applying for registration of dietary supplement based on 1-MNA as new foodstuff within the European procedure. The studies demonstrated no genotoxicological properties of 1-MNA in vitro micronucleus test on human lymphocytes.

With the successful conclusion of the above studies, the Company intends to promptly submit its application to authorise dietary supplement containing 1-MNA as new foodstuff in an EU member state of its choice. Positive registration will open EU markets for the product. The Company intends to register the dietary supplement in 2013.

The 1-MNA dietary supplement is an innovative product that has a capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development. Placing on the market of the innovative dietary supplement (new foodstuff) based on 1-MNA, which is used to meet special nutritional needs in the prevention of atherosclerosis, will become a new area of the Company's operations. It is estimated that only in Poland there are 18 million people threatened with atherosclerosis, of which only 8 million is aware of that fact. Atherosclerosis is one of the most significant civilisation diseases, and together with cancer, it is one of the most common causes of death in the world. The market of OTC products in Poland in the category "Heart and vascular system" was estimated at 271 million PLN in 2011 (according to IMS). Within 3 years from the introduction of the product, the Company intends to reach market share of 6%, and eventually of 12%. Moreover, having registered the 1-MNA dietary supplement within the European procedure, the Company intends to receive revenue from sale (or licence for sale) of the product on EU markets.

The European procedure is an application procedure compliant with the provisions of Art. 4 of Regulation (EC) no. 258/97 of the European Parliament and of the Council of 27th January 1997, which proves the safety and purposefulness of the use of novel food ingredient. Within this procedure, the entity responsible for placing on the Community market submits appropriate application to EU member state, where the new foodstuff is to be first placed on the market. An additional scientific assessment is performed at European level by European Food Safety Authority. Following the assessment, the European Commission, by relevant supervision authorities, grants permission for placing the new foodstuff on the market.

The information is made public due to the fact that introduction of innovative dietary supplement 1-MNA on the market may have a significant influence on the Company's financial situation in the next few years.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board